Navigation Links
Lasker Foundation Welcomes Elias Zerhouni to Board of Directors
Date:2/3/2009

Former Director of National Institutes of Health

NEW YORK, Feb. 3 /PRNewswire/ -- The Albert and Mary Lasker Foundation announced today the election of Dr. Elias A. Zerhouni, the immediate past director of the National Institutes of Health and leader in biomedical research, to its Board of Directors.

"We are delighted that Dr. Zerhouni has agreed to join our Board of Directors," said Dr. Maria C. Freire, President of the Lasker Foundation. "The Lasker Foundation is entering a new era of opportunities for scientific advancement with the bold vision and spirit that drove our founders to transform the landscape of biomedical research. Dr. Zerhouni's vast experience will be a great asset to the Foundation."

"I am honored and I am looking forward to contributing to the noble missions of the Lasker Foundation in these days of rapid and challenging transformations in science and health," said Dr. Zerhouni.

Dr. Alfred Sommer, Chairman of the Lasker Foundation and Dean Emeritus of the Bloomberg School of Public Health of Johns Hopkins University, joined Dr. Freire in expressing his enthusiasm. He said, "Dr. Zerhouni is a highly-respected leader in medicine worldwide, and he will bring much to the Board's deliberations."

Dr. Zerhouni served as director of the US National Institutes of Health (NIH) the world's foremost biomedical research agency from 2002 to 2008. He launched the NIH Roadmap for Medical Research in 2003 to fund compelling initiatives that no single NIH institute could support and established a series of new programs to encourage high-risk innovative research, to enhance interdisciplinary research at the interface of the physical and biological sciences, and to increase support for the independence of early career scientists. During his tenure, NIH tripled its international funding for global health, and it launched comprehensive plans for health disparities, obesity research, and the neurosciences.

About the Lasker Foundation:

The Albert and Mary Lasker Foundation fosters the prevention and treatment of disease and disabilities by honoring excellence in basic and clinical science, by educating the public, and by advocating for support of medical research.

Founded in 1942, the Lasker Foundation presents the prestigious Lasker Awards, which recognize the world's leaders in basic and clinical medical research, and individuals with outstanding public service. For much of the 20th Century, the Lasker Foundation was led by Mary Lasker, who was America's most prominent citizen-activist for public investment in medical research. Mary Lasker is widely credited with prodding the White House and the Congress to greatly expand federal funding for medical research, particularly through the National Institutes of Health.

Further information about the Albert and Mary Lasker Foundation is available at www.laskerfoundation.org.


'/>"/>
SOURCE The Albert and Mary Lasker Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Discoverers of Small Regulatory RNAs and Cholesterol-Lowering Drugs to Receive Lasker Awards for Medical Research
2. Foundation Kicks off First-Ever PLS Awareness Month
3. Smithfield Foods Lean Generation(R) Deli Partnership with National Breast Cancer Foundation Celebrates $135,000 Contribution
4. National Patient Advocate Foundation Founder Testifies Before U.S. Senate Health Committee on Methods to Improve Healthcare Quality and Patient Outcomes
5. Today Show and American Legacy Foundation(R) Team Up to Help Smokers Call it Quits
6. The SCAN Foundation Grants $5 Million to the Health Technology Center to Establish National Center for Technology and Aging
7. Defeat Diabetes Foundation Announces R & B Singer Howard Hewett as National Spokesperson
8. Dave Annable Named Christopher & Dana Reeve Foundation Ambassador
9. Glaucoma Research Foundation to Hold Annual Fundraising Benefit
10. The SCAN Foundation Funds New Program for Santa Clarita and South Los Angeles Seniors and Those Who Care for Them
11. Michael J. Fox Foundation Awards $2.5 Million for Parkinsons Drug Development Projects Led By Academic Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: